drugset / Trial / NCT05355350
PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections
Phase 4
Withdrawn
Rambam Health Care Campus
Hadassah Medical Organization · collabRabin Medical Center · collabThe Chaim Sheba Medical Center · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Data regarding optimal treatment for extended-spectrum beta-lactamase (ESBL) producing Enterobacterales bloodstream infection are lacking. Observational studies show conflicting results when comparing treatment with combination beta-lactam-beta-lactamase inhibitor and carbapenems. The investigators aim to evaluate the effect of definitive treatment with meropenem vs. piperacillin-tazobactam on the outcome of patients with bacteremia due to cephalosporin-non-susceptible Enterobacteriaceae. The investigators hypothesize that piperacillin-tazobactam is non-inferior to meropenem.
Timeline
- Start
- 2022-07-01
- Primary completion
- 2025-07-21
- Completion
- 2025-07-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Meropenem | Small molecule | 1 g | — |
| Subject | Piperacillin | Small molecule | — | — |
| Subject | Tazobactam | Small molecule | — | — |